Nutraceutix specialty pharmaceutical company, develops and commercializes prescription, over-the-counter, and nutritional products. The company uses its controlled delivery technology platform and develops water soluble and insoluble drugs, as well as high and low dose drugs; analgesic, cardiovascular, diabetes, anti-nausea, and pulmonary products; and dietary supplement products, including combinations of glucosamine and chondroitin, calcium, and other dietary products. Its lead drug product candidates include a 12 hour extended release formulation of ibuprofen, an analgesic for the treatment of pain, fever, and inflammation, which has completed Phase III clinical trial; and 12 hour Pseudoephedrine, a decongestant that is used to relieve sinus pressure related to allergies and common cold.